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To the Editor: We read with great interest the paper by
Gonza´lez et al.1 entitled, ‘early steroid treatment improves the
recovery of renal function in patients with drug-induced
acute interstitial nephritis’ that appeared in Kidney Inter-
national, April 2008. We have a short comment on the
conclusion of this study that we would like to share with the
readers.
Briefly, the investigators in this study reviewed 61 cases of
biopsy-proven drug-induced acute interstitial nephritis, 52 of
them were treated with steroids. Among the patients
who received steroid treatment, they compared the group of
patients who had full recovery of their renal function
(28 patients) to those who failed to have full recovery
(24 patients). As a result, they reported the following significant
differences:
K Longer period from the time of the discontinuation of
the offending drug to the time of performing diagnostic
kidney biopsy in the group with incomplete recovery of
renal function.
K Longer period from the time of the discontinuation of
the offending drug to the time of initiation of steroid
therapy in the group with incomplete recovery of renal
function.
The authors concluded that the delayed initiation of
steroid therapy contributed to the incomplete recovery of
renal function. We wish to raise a concern regarding this
conclusion.
It is plausible that the group of patients who received early
treatment included patients whose renal function would have
improved solely from drug withdrawal and not necessarily
from steroid therapy, and, therefore, would fall in the full
recovery group. On the other hand, the group of patients
who received delayed treatment was less likely to include
patients who would have improved solely from drug
discontinuation as the decision to biopsy these patients was
obviously taken when such improvement had not been
apparent, and, therefore, more of these patients would have
fallen in the incomplete recovery group.
Just as one would generally argue in such retrospective
studies that initiation of treatment versus no treatment
would select for severe cases in the treated group, the
initiation of late treatment versus early treatment could very
well select for intractable cases in the delayed treatment
group.
1. Gonza´lez E, Gutie´rrez E, Galeano C et al. Early steroid treatment improves
the recovery of renal function in patients with drug-induced acute
interstitial nephritis. Kidney Int 2008; 73: 940–946.
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Karnib and Ziyadeh raise a concern regarding the
conclusions of our study ‘Early steroid treatment improves
the recovery of renal function in patients with drug-
induced acute interstitial nephritis’.1 They suggest that
patients who received early treatment could include
patients whose renal function would have improved from
drug withdrawal as the only therapeutic measure, whereas
the group who received delayed steroid treatment was less
likely to include this kind of patient. We think that there
are no data in our study that could support this
speculation. We included only patients with biopsy-proven
drug-induced acute interstitial nephritis and we analyzed
the long-term outcome of renal function (mainly the
recovery of baseline renal function) in relationship with
several clinical and histologic parameters. Treatment with
steroids and particularly the delay between drug with-
drawal and onset of steroid therapy were carefully
analyzed. Almost half of the patients who did not receive
steroids remained on chronic dialysis, and in the remain-
ing patients we found a significant correlation between the
delay in steroid treatment and the final serum creatinine.
The only significant differences by multiple logistic
regression analysis between patients with a complete
(group 1a) or incomplete (group 1b) recovery of renal
function were an interval longer than 7 days between drug
withdrawal and onset of steroid treatment, and the severity
of interstitial fibrosis. This latter point, in turn, was related
to the delay in steroid treatment. Those patients in whom
repeated renal biopsies were performed showed a rapid
transformation of the initial interstitial cellular infiltrates
into large areas of fibrosis when steroids were delayed.
Obviously, selection bias is common in this type of
retrospective analysis, but in our opinion a possible
selection bias in our study would work against the
hypothesis of Karnib and Ziyadeh: early renal biopsy
indication and early steroid treatment would have been
allocated to those patients with a more unfavorable
prognosis and who were less likely to recover renal
function with only the withdrawal of the responsible drug.
We agree that a prospective, randomized trial to analyze
the influence of steroids in the outcome of drug-induced
acute interstitial nephritis is the only way to completely
eliminate such possible bias, but it will be very difficult to
develop. Meanwhile, our study provides strong clinical and
histologic data to support our conclusions: steroids should
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be started promptly after the diagnosis of drug-induced
acute interstitial nephritis to avoid subsequent interstitial
fibrosis (that rapidly replaces, in the absence of steroids,
the interstitial cellular infiltrates typical of drug-induced
acute interstitial nephritis) and an incomplete recovery of
renal function.
1. Gonza´lez E, Gutie´rrez E, Galeano C et al. Early steroid treatment improves
the recovery of renal function in patients with drug-induced acute
interstitial nephritis. Kidney Int 2008; 73: 940–946.
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We write with reference to the recently published manuscript
by Jorsal et al.1 They observe an association between genetic
variation within the adiponectin gene (rs17300539, G4A
variant) and nephropathy in a cross-sectional study. The A
allele frequency was 0.094 in the nephropathy group
compared to 0.066 in those with normoalbuminuria
(P¼ 0.01). Furthermore, the authors have previously ob-
served this association in another larger study where the A
allele was associated with an approximate 50% increase in
nephropathy risk.2
We have also examined this association. Sex-matched
samples were genotyped from 98 patients with type 1
diabetes (T1DM) and nephropathy,3 99 patients with
T1DM without nephropathy (Golden Years protected
patients)4 and 42 controls. The Golden Years patients have
had T1DM for at least 50 years and so are at extremely low
risk of renal complications. These patients were significantly
older (mean age of 82 years) and had a longer duration of
diabetes (66.9 years) compared to those with nephropathy
(58 years of age and 40 years duration), and controls (55
years of age). As shown in Table 1, we observed that the
frequency of the rare allele (A) was twice as high in those with
nephropathy (0.152) compared to those without (0.078),
P¼ 0.01. The odds ratio for nephropathy associated with the
A allele within the combined groups was 2.12 (95% CI
0.86–5.23), P¼ 0.02.
Our data replicate the previous associations described for
this gene variant. Further, prospective work is essential to
confirm this association.
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Table 1 | Genotype distribution of the rs17300539, G to A
variant in relation to nephropathy
Allele
Nondiabetic
controls
Golden Years
T1DM
Nephropathy
T1DM
GG 38 83 69
GA 3 15 28
AA 1 1 1
Hardy–Weinberg
P-value
0.22 0.73 0.31
Rare allele (A)
frequency
0.06* 0.086+ 0.152*,+
95% CI 0.01–0.11 0.05–0.12 0.1–0.2
T1DM, type 1 diabetes mellitus.
*Po0.01, +Po0.05.
Nephropathic vs combined Golden Years and controls, P=0.01. No difference was
observed in genotype distribution between Golden Years and controls.
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